A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B
✍ Scribed by E. K. MANESIS; G. V. PAPATHEODORIDIS; S. J. HADZIYANNIS
- Book ID
- 108604384
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 87 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0269-2813
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ؍ 60
The course of chronic hepatitis B was studied in 30 patients who had antibody to hepatitis e antigen and hepatitis B virus DNA in the serum and hepatitis B core antigen in the liver. Over a 2-year period, no patient experienced a sustained spontaneous remission of disease, and follow-up liver histol